MesotheliomaCenter's

Mesothelioma-Line

Curated Journal Articles on Mesothelioma

Category Archives: Chemotherapy

Moderately Hypofractionated Helical IMRT, FDG-PET/CT-guided, for Progressive Malignant Pleural Mesothelioma in Patients With Intact Lungs.

Clinical Lung Cancer 2018 September 3 [Link] Fodor A1, Broggi S2, Incerti E3, Dell’Oca I4, Fiorino C2, Samanes Gajate AM3, Pasetti M4, Cattaneo MG2, Passoni P4, Gianolli L3, Calandrino R2, Picchio M, Di Mu Abstract INTRODUCTION: The objective of this study was to present the outcomes of moderately hypofractionated helical intensity-modulated radiation therapy (HT) with/without […]

Comments Off on Moderately Hypofractionated Helical IMRT, FDG-PET/CT-guided, for Progressive Malignant Pleural Mesothelioma in Patients With Intact Lungs.

Intensity-modulated radiotherapy is a safe and effective treatment for localized malignant pleural mesothelioma.

Thoracic Cancer 2018 September 21 [Link] Simon M, Shochat T, Peled N, Zer A, Kramer MR, Eldan O, Saute M, Dudnik ER, Allen AM Abstract BACKGROUND: Malignant pleural mesothelioma (MPM) is a rare disease and management of localized disease is controversial. Radiotherapy has been shown to be useful after extrapleural pneumonectomy (EPP), as well as […]

Comments Off on Intensity-modulated radiotherapy is a safe and effective treatment for localized malignant pleural mesothelioma.

Zoledronic acid in the management of mesothelioma – a feasibility study (Zol-A Trial): study protocol for a randomised controlled trial.

Trials 2018 August 29 [Link] de Fonseka D, Morley A, Stadon L, Keenan E, Walker S, Smith S, Harvey JE, Cox RA, Dangoor A, Comins C, Rogers C, Edey A, Addeo A, Maskell NA Abstract BACKGROUND: Nitrogen containing bisphosphonates such as zoledronic acid (ZA) are known to contain certain anti-cancer properties. These have been investigated […]

Comments Off on Zoledronic acid in the management of mesothelioma – a feasibility study (Zol-A Trial): study protocol for a randomised controlled trial.

Gemcitabine synergizes with immune checkpoint inhibitors and overcomes resistance in a preclinical model and mesothelioma patients.

Clinical Cancer Research 2018 August 28 [Link] Tallon de Lara P, Cecconi V, Hiltbrunner S, Yagita H, Friess M, Bode-Lesniewska B, Opitz I, Vrugt B, Weder W, Stolzmann P, Felley-Bosco E, Stahel RA, Tischler V, Britschgi C, Soldini D, van den Broek M, Curioni Fontecedro A Abstract

Comments Off on Gemcitabine synergizes with immune checkpoint inhibitors and overcomes resistance in a preclinical model and mesothelioma patients.

BAMLET kills chemotherapy-resistant mesothelioma cells, holding oleic acid in an activated cytotoxic state.

PloS One 2018 August 29 [Link] Rath EM, Cheng YY, Pinese M, Sarun KH, Hudson AL, Weir C, Wang YD, Håkansson AP, Howell VM, Liu GJ, Reid G, Knott RB, Duff Abstract Malignant pleural mesothelioma is an aggressive cancer with poor prognosis. Here we have investigated in vitro efficacy of BAMLET and BLAGLET complexes (anti-cancer […]

Comments Off on BAMLET kills chemotherapy-resistant mesothelioma cells, holding oleic acid in an activated cytotoxic state.

Current treatments and trials in malignant pleural mesothelioma.

The Clinical Respiratory Journal 2018 July 12 [Link] Bibby AC, Maskell NA Abstract OBJECTIVES: This article aims to review the evidence from recent clinical trials in mesothelioma, and to provide an overview of relevant clinical trials that are currently in progress. DATA SOURCE: Ovid MEDLINE, 1946 to present. STUDY SELECTION: Clinical trials of therapeutic interventions […]

Comments Off on Current treatments and trials in malignant pleural mesothelioma.

Hypoxia promotes acquisition of aggressive phenotypes in human malignant mesothelioma.

BMC Cancer 2018 August 15 [Link] Kim MC, Hwang SH, Kim NY, Lee HS, Ji S, Yang Y, Kim Y Abstract BACKGROUND: Hypoxia is a hallmark of the solid tumor microenvironment and is associated with poor outcomes in cancer patients. The present study was performed to investigate mechanisms underlying the hypoxia-induced phenotypic changes using human […]

Comments Off on Hypoxia promotes acquisition of aggressive phenotypes in human malignant mesothelioma.

Inhibition of MDM2 via Nutlin-3A: A Potential Therapeutic Approach for Pleural Mesotheliomas with MDM2-Induced Inactivation of Wild-Type P53.

Journal of Oncology 2018 July 17 Link] Walter RFH, Werner R, Wessolly M, Mairinger E, Borchert S, Schmeller J, Kollmeier J, Mairinger T, Hager T, Bankfalvi A, Christoph DC, Eberhardt WEE, Plönes T, Aigner C, Schmid KW, Wohlschlaeger J, Mairinger FD Abstract Previously, our group demonstrated that nuclear expression of E3 ubiquitin ligase (MDM2) in […]

Comments Off on Inhibition of MDM2 via Nutlin-3A: A Potential Therapeutic Approach for Pleural Mesotheliomas with MDM2-Induced Inactivation of Wild-Type P53.

A systematic review and meta-analysis of second-line therapies for treatment of mesothelioma.

Respiratory Medicine 2018 August [Link] Petrelli F, Ardito R, Conti B, Coinu A, Cabiddu M, Ghilardi M, Borgonovo K, Barni S, Ghidini Ah3>Abstract Malignant plINTRODUCTION: Advanced malignant pleural mesothelioma (MPM) is generally treated with platinum/pemetrexed-based first-line therapy. Once the disease progresses, evidence for the efficacy of palliative treatments is lacking, and platinum re-challenge or single-agent […]

Comments Off on A systematic review and meta-analysis of second-line therapies for treatment of mesothelioma.

Combined hyaluronate-based films loaded with pemetrexed and cisplatin for the treatment of malignant pleural mesothelioma: Preliminary evaluation in an orthotopic tumor recurrence model.

European Journal of Pharmaceutical Sciences 2018 July 17 [Link] Sonvico F, Barbieri S, Colombo P, Barocelli E, Mucchino C, Cantoni AM, Petronini PG, Rusca M, Carbognani P, Ampoll Abstract Malignant pleural mesothelioma (MPM) is a rare malignancy characterized by a long latency period of 20-50 years after exposure to the main aetiology agent that is asbestos. […]

Comments Off on Combined hyaluronate-based films loaded with pemetrexed and cisplatin for the treatment of malignant pleural mesothelioma: Preliminary evaluation in an orthotopic tumor recurrence model.